AZNAstraZenecaSigning up patients
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non-Hodgkin Lymphoma · Follicular Lymphoma (FL) · Large B-Cell Lymphoma (LBCL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 270 (planned)
- Started
- Nov 27, 2024
- Main results expected
- Apr 21, 2028
- Fully finished
- Oct 21, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall response rate (ORR) (central review)
Measured over: Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06526793 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC